Celanese Announces Agreement with the Population Council for Sustained Release Dual-API Therapeutic
Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, today announced that it has entered into an agreement with the Population Council to supply its VitalDose® Drug Delivery Platform for use in a new Multipurpose Prevention Technology (MPT) Intravaginal Ring (IVR).
- Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, today announced that it has entered into an agreement with the Population Council to supply its VitalDose® Drug Delivery Platform for use in a new Multipurpose Prevention Technology (MPT) Intravaginal Ring (IVR).
- The IVR is being developed to provide both contraception and protection against HIV and is currently in a phase 1b clinical trial.
- Long-acting continuous drug delivery dose forms, like IVRs, offer fewer barriers to reliable use than oral forms requiring daily doses.
- Providing benefits for patients, like enhanced convenience, can lead to better outcomes and is the driver for developing patient-centric dose forms.